Abstract
Breast implant-associated squamous cell carcinoma (BIA-SCC) is a rare but serious disease that originates from the lining of the breast implant capsule. Alongside BIA-anaplastic large cell lymphoma, the U.S. Food and Drug Administration issued a safety communication in 2022 regarding BIA-SCC to alert healthcare providers and patients. Although only a few cases have been reported, the high mortality and poor prognosis associated with BIA-SCC underscore the severity of the disease. This review discusses the current knowledge of BIA-SCC, including its pathogenesis, diagnostic methods, and treatment options based on reported cases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
